Q1 2025 Surgical Science Sweden AB Earnings Call Transcript
Key Points
- Sales increased by 30% in local currencies, reaching SEK 251 million, up from SEK 188 million last year.
- The acquisition of Intelligent Ultrasound positions Surgical Science Sweden AB (SUSRF) as a world leader in ultrasound simulation, with promising synergies in distribution and product development.
- The company achieved an all-time high in license revenue, growing by 33% to SEK 84 million, driven by the expanding robotic surgery market.
- The new sales organization has shown positive results in terms of sales, customer satisfaction, and efficiency.
- The strategic review initiated aims to capitalize on numerous growth opportunities, indicating a proactive approach to future expansion.
- One-off costs related to the acquisition and integration of Intelligent Ultrasound negatively impacted profits in Q1.
- Sales for Intelligent Ultrasound were lower than expected, particularly in the UK due to NHS budget constraints.
- There is continued pressure on purchasing budgets in key markets like the US, affecting sales of educational products.
- The company revised its sales target for 2026 from SEK 1.5 billion to SEK 1.4 billion due to global trade uncertainties and slower-than-expected regulatory approvals.
- The adjusted EBIT margin target for 2026 was revised down to 25-30% from the previously stated 40%, reflecting lower license revenues and increased investment needs.
Welcome to Surgical Science Q1 report 2025 presentation.
(Operator Instructions).
Now I will hand over to the speakers, CEO Tom Englund and CFO Anna Ahlberg. Please go.
Welcome to this quarter one presentation for Surgical Science. My name is Tom Englund. I'm the CEO of Surgical Science, and with me today I have Anna Ahlberg, our company CFO.
We will use our time together today to first present the report and then we will take questions from the audience. We can look back at an eventful and positive first quarter for surgical science and a good start for 2025. This was an eventful quarter for us with strong growth and good underlying profitability.
Sales increased to SEK 251 million, up from SEK188 million last year, with a growth of 30% in local currencies. During the quarter, we also reached an all-time high for our important license revenue, which grew more than 30% as the robotic surgery market continues to expand. I will now present the most important
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
